AstraZeneca
๐ฌ๐งUnited Kingdom
- Country
- ๐ฌ๐งUnited Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Solid Tumours
- Interventions
- First Posted Date
- 2014-02-06
- Last Posted Date
- 2015-11-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT02056392
- Locations
- ๐บ๐ธ
Research Site, Overland Park, Kansas, United States
Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.
Phase 4
Terminated
- Conditions
- Non-ST Elevation Acute Coronary Syndrome
- Interventions
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2016-05-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 34
- Registration Number
- NCT02052635
- Locations
- ๐บ๐ธ
Research Site, Rapid City, South Dakota, United States
Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults
Phase 1
Completed
- Conditions
- Alzheimer's DiseaseMemory Impairment
- Interventions
- First Posted Date
- 2014-01-31
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT02051335
Clinical Practice of AECOPD Management in China
Completed
- Conditions
- Acute Exacerbation of Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2014-01-31
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5095
- Registration Number
- NCT02051166
- Locations
- ๐จ๐ณ
Research Site, Tianjin, China
To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT02046850
- Locations
- ๐บ๐ธ
Research Site, Overland Park, Kansas, United States
A Study to Evaluate the Clinical Epidemiology of Patients With Heart Failure (HF) in India
Withdrawn
- Conditions
- Heart Failure
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT02047526
AZD3293 Thorough QT Study in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2014-07-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 52
- Registration Number
- NCT02040987
- Locations
- ๐บ๐ธ
Research Site, Baltimore, Maryland, United States
Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects
Phase 1
Completed
- Conditions
- Healthy VolunteersPharmacologic Action
- Interventions
- Drug: AZD3293 oral solutionDrug: AZD3293 tablet formulation ADrug: AZD3293 tablet formulation B
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2014-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1
- Registration Number
- NCT02039180
- Locations
- ๐บ๐ธ
Research Site, Cypress, California, United States
SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.
Phase 1
Completed
- Conditions
- Mild-Moderate Alzheimer's DiseaseHealthy Elderly
- Interventions
- Biological: MEDI1814 for Subcutaneous InjectionBiological: MEDI1814 for IV injectionBiological: Placebo for Subcutaneous InjectionBiological: IV Placebo
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2019-06-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 77
- Registration Number
- NCT02036645
- Locations
- ๐บ๐ธ
Research Site, Salt Lake City, Utah, United States
D2212C00002 J-Phase II Study
Phase 2
Completed
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Biological: tralokinumab cohort 1Biological: tralokinumab cohort 2Other: Placebo
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 37
- Registration Number
- NCT02036580
- Locations
- ๐ฏ๐ต
Research Site, Yokohama-shi, Japan